WKB Lawyers advised USP Group on the acquisition of assets related to the “Trilac” brand

The WKB Lawyers team advised USP Group on the acquisition of assets related to the “Trilac” medicinal product from Zakład Farmaceutyczny AMARA.

The project required comprehensive legal support combining transactional, regulatory and intellectual property expertise, as well as practical knowledge of the pharmaceutical and life sciences sector.

WKB Lawyers supported the client at all stages of the process, providing advice on due diligence, as well as the negotiation and preparation of the complete transaction documentation.

The WKB Lawyers team was led by Sebastian Woźniak, supervised by Jakub Jędrzejak, with support from Zuzanna Cybulska. Regulatory matters were handled by Anna Wiktorow-Bojska and Ewa Owerczuk, while intellectual property support was provided by Anna Grzywacz.

USP Group operates in Poland through, among others, USP Zdrowie, the market leader in over-the-counter (OTC) products and medicines. USP Zdrowie’s portfolio includes leading brands on the Polish OTC market, such as Apap, Ibuprom, and Gripex, as well as numerous dietary supplements and medical devices. USP Zdrowie’s commitment to the high quality and efficacy of its products has earned the lasting trust of consumers, patients, and pharmacists alike.

For more information about the company, visit: www.uspzdrowie.pl

Zakład Farmaceutyczny Amara is a Polish manufacturer of medicinal products, dietary supplements, medical devices and dermatological cosmetics. The company has been active in the pharmaceutical market for over 25 years, cooperating with pharmacies, commercial partners and distributors across Poland. Amara develops and manufactures a broad portfolio of products based on both traditional formulations and modern manufacturing technologies, while also providing contract manufacturing. The company combines pharmaceutical expertise with high quality and safety standards.